Jazz Pharmaceuticals (JAZZ) Revenue & Revenue Breakdown
Jazz Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$3.83B
Latest Revenue (Q)
$1.02B
Main Segment (Y)
Product And Services, Product Sales Net Of Deductions
Main Geography (Y)
UNITED STATES
Jazz Pharmaceuticals Revenue by Period
Jazz Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.83B | 4.78% |
| 2022-12-31 | $3.66B | 18.26% |
| 2021-12-31 | $3.09B | 30.91% |
| 2020-12-31 | $2.36B | 9.34% |
| 2019-12-31 | $2.16B | 14.32% |
| 2018-12-31 | $1.89B | 16.82% |
| 2017-12-31 | $1.62B | 8.79% |
| 2016-12-31 | $1.49B | 12.32% |
| 2015-12-31 | $1.32B | 12.95% |
| 2014-12-31 | $1.17B | 34.44% |
| 2013-12-31 | $872.42M | 48.88% |
| 2012-12-31 | $585.98M | 115.21% |
| 2011-12-31 | $272.28M | 56.68% |
| 2010-12-31 | $173.78M | 35.29% |
| 2009-12-31 | $128.45M | 90.26% |
| 2008-12-31 | $67.51M | 3.39% |
| 2007-12-31 | $65.30M | 45.58% |
| 2006-12-31 | $44.86M | 109.20% |
| 2005-12-31 | $21.44M | 100.00% |
| 2004-12-31 | - | - |
Jazz Pharmaceuticals generated $3.83B in revenue during NA 2023, up 4.78% compared to the previous quarter, and up 202.77% compared to the same period a year ago.
Jazz Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.02B | 13.51% |
| 2024-03-31 | $901.98M | -10.87% |
| 2023-12-31 | $1.01B | 4.09% |
| 2023-09-30 | $972.14M | 1.55% |
| 2023-06-30 | $957.32M | 7.22% |
| 2023-03-31 | $892.81M | -8.16% |
| 2022-12-31 | $972.12M | 3.35% |
| 2022-09-30 | $940.65M | 0.83% |
| 2022-06-30 | $932.88M | 14.64% |
| 2022-03-31 | $813.72M | -9.26% |
| 2021-12-31 | $896.73M | 6.99% |
| 2021-09-30 | $838.12M | 11.48% |
| 2021-06-30 | $751.81M | 23.74% |
| 2021-03-31 | $607.58M | -8.71% |
| 2020-12-31 | $665.52M | 10.76% |
| 2020-09-30 | $600.89M | 6.84% |
| 2020-06-30 | $562.44M | 5.18% |
| 2020-03-31 | $534.73M | -8.08% |
| 2019-12-31 | $581.74M | 8.19% |
| 2019-09-30 | $537.70M | 0.67% |
| 2019-06-30 | $534.13M | 5.11% |
| 2019-03-31 | $508.19M | 6.66% |
| 2018-12-31 | $476.46M | 1.51% |
| 2018-09-30 | $469.37M | -6.22% |
| 2018-06-30 | $500.48M | 12.57% |
| 2018-03-31 | $444.61M | 1.88% |
| 2017-12-31 | $436.40M | 5.96% |
| 2017-09-30 | $411.86M | 4.43% |
| 2017-06-30 | $394.39M | 4.88% |
| 2017-03-31 | $376.05M | -5.19% |
| 2016-12-31 | $396.62M | 6.00% |
| 2016-09-30 | $374.18M | -1.83% |
| 2016-06-30 | $381.16M | 13.44% |
| 2016-03-31 | $336.01M | -1.43% |
| 2015-12-31 | $340.88M | 0.00% |
| 2015-09-30 | $340.87M | 2.13% |
| 2015-06-30 | $333.75M | 7.90% |
| 2015-03-31 | $309.30M | -5.74% |
| 2014-12-31 | $328.14M | 7.03% |
| 2014-09-30 | $306.58M | 5.27% |
| 2014-06-30 | $291.23M | 17.95% |
| 2014-03-31 | $246.92M | 4.73% |
| 2013-12-31 | $235.77M | 1.56% |
| 2013-09-30 | $232.16M | 11.48% |
| 2013-06-30 | $208.25M | 6.12% |
| 2013-03-31 | $196.24M | 6.82% |
| 2012-12-31 | $183.70M | 4.67% |
| 2012-09-30 | $175.51M | 35.49% |
| 2012-06-30 | $129.54M | 19.49% |
| 2012-03-31 | $108.41M | 29.78% |
| 2011-12-31 | $83.54M | 13.98% |
| 2011-09-30 | $73.29M | 13.51% |
| 2011-06-30 | $64.57M | 26.90% |
| 2011-03-31 | $50.88M | -4.66% |
| 2010-12-31 | $53.37M | 19.25% |
| 2010-09-30 | $44.75M | 10.54% |
| 2010-06-30 | $40.49M | 15.11% |
| 2010-03-31 | $35.17M | -8.13% |
| 2009-12-31 | $38.28M | 24.26% |
| 2009-09-30 | $30.81M | -17.36% |
| 2009-06-30 | $37.28M | 68.87% |
| 2009-03-31 | $22.08M | 12.66% |
| 2008-12-31 | $19.59M | 10.42% |
| 2008-09-30 | $17.75M | 14.20% |
| 2008-06-30 | $15.54M | 6.18% |
| 2008-03-31 | $14.63M | -5.45% |
| 2007-12-31 | $15.48M | - |
Jazz Pharmaceuticals generated $1.02B in revenue during Q2 2024, up 13.51% compared to the previous quarter, and up 114.67% compared to the same period a year ago.
Jazz Pharmaceuticals Revenue Breakdown
Jazz Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Epidiolex/Epidyolex | $736.40M | $463.64M | - | - | - |
| Defitelio/Defibrotide | $194.29M | $197.93M | $195.84M | $172.94M | $149.45M |
| Zepzelca | $269.91M | $246.81M | $90.38M | - | - |
| Xywav | $958.42M | $535.30M | $15.26M | - | - |
| Xyrem | $1.02B | $1.27B | $1.74B | $1.64B | $1.40B |
| Vyxeos | $127.98M | $134.06M | $121.11M | $121.41M | $100.83M |
| Total Oxybate | $1.98B | $1.80B | $1.76B | - | - |
| Sunosi | $28.84M | $57.91M | $28.33M | $3.71M | - |
| Sativex | $16.82M | $12.71M | - | - | - |
| Rylaze | $281.66M | $85.63M | - | - | - |
| Product And Services, Royalties And Contract Revenue | $17.95M | $15.24M | $16.91M | $26.16M | $21.45M |
| Product And Services, Product Sales Net Of Deductions | $3.64B | $3.08B | $2.35B | - | - |
| Other Products | $6.64M | $9.80M | $6.84M | $17.55M | $18.75M |
| Neuroscience | $2.76B | $2.34B | $1.79B | - | - |
| Oncology | $873.84M | $733.81M | $554.46M | - | - |
| Erwinaze And Erwinase | - | $69.38M | $147.14M | $177.47M | $174.74M |
| Product And Services, Product Sales | - | - | - | $2.14B | $1.87B |
| Prialt | - | - | - | - | $20.84M |
Jazz Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product And Services, Product Sales Net Of Deductions (28.20%), Neuroscience (21.38%), Total Oxybate (15.32%), Xyrem (7.90%), Xywav (7.42%), Oncology (6.77%), Epidiolex/Epidyolex (5.70%), Rylaze (2.18%), Zepzelca (2.09%), Defitelio/Defibrotide (1.50%), Vyxeos (0.99%), Sunosi (0.22%), Product And Services, Royalties And Contract Revenue (0.14%), Sativex (0.13%), and Other Products (0.05%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sativex | $6.38M | $2.73M | $2.81M | $7.10M | $4.72M | $3.22M | $4.14M | $4.74M | $4.65M | $6.10M | $1.96M | - | - | - | - | - | - | - | - | - |
| Other Products | $2.70M | $3.57M | $3.42M | $3.43M | $3.07M | $1.00M | $1.63M | $943.00K | $1.03M | $3.34M | $2.64M | $2.78M | $1.60M | $1.87M | $852.00K | $2.52M | $4.23M | $4.48M | $5.17M | $3.67M |
| Epidiolex/Epidyolex | $247.10M | $198.72M | $202.23M | $188.91M | $207.00M | $196.22M | $175.29M | $157.89M | $193.79M | $160.38M | $109.48M | - | - | - | - | - | - | - | - | - |
| Defitelio/Defibrotide | $45.42M | $47.68M | $46.11M | $39.08M | $40.65M | $49.45M | $54.70M | $49.49M | $42.51M | $57.70M | $48.10M | $49.62M | $55.45M | $50.24M | $42.71M | $47.43M | $47.78M | $37.60M | $46.05M | $41.50M |
| Zepzelca | $81.05M | $75.10M | $70.35M | $67.18M | $71.97M | $70.32M | $68.28M | $59.34M | $64.84M | $71.71M | $55.92M | $54.33M | $53.44M | $36.94M | - | - | - | - | - | - |
| Xywav | $368.47M | $315.30M | $326.56M | $277.76M | $281.38M | $255.94M | $235.03M | $186.08M | $182.65M | $153.06M | $124.16M | $75.42M | - | - | - | - | - | - | - | - |
| Xyrem | $62.18M | $64.23M | $159.77M | $178.13M | $247.50M | $256.04M | $269.42M | $247.50M | $288.76M | $307.33M | $334.18M | $335.55M | $439.27M | $447.81M | $446.81M | $407.88M | $435.35M | $425.64M | $413.21M | $368.32M |
| Vyxeos | $43.01M | $32.02M | $34.06M | $36.70M | $30.27M | $30.07M | $33.89M | $33.76M | $34.76M | $34.69M | $31.45M | $33.16M | $30.99M | $30.82M | $26.57M | $32.72M | $31.52M | $29.58M | $31.36M | $28.94M |
| Total Oncology | $277.31M | $257.55M | $252.21M | $228.89M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product And Services, Product Sales Net Of Deductions | $964.14M | $842.10M | $946.99M | $884.22M | $967.53M | $935.77M | $928.30M | $809.84M | $892.88M | $834.25M | $748.34M | $603.53M | $661.30M | $596.95M | - | - | - | - | - | - |
| Total Oxybate | - | - | $486.33M | $455.89M | $528.88M | $511.98M | $504.45M | $433.58M | $471.42M | $460.40M | $458.35M | $410.97M | - | - | - | - | - | - | - | - |
| Sunosi | - | - | - | - | - | - | $12.97M | $15.88M | $14.93M | $19.25M | $12.12M | $11.61M | $8.71M | $9.12M | $8.58M | $1.92M | $2.73M | $987.00K | - | - |
| Rylaze | - | - | $101.69M | $85.93M | $80.97M | $73.51M | $72.95M | $54.22M | $64.95M | $20.67M | - | - | - | - | - | - | - | - | - | - |
| Neuroscience | - | - | - | - | $740.60M | $711.41M | $696.84M | $612.09M | $684.79M | $646.12M | $581.91M | $422.57M | - | - | - | - | - | - | - | - |
| Oncology | - | - | - | - | $223.86M | $223.35M | $229.82M | $196.80M | $207.07M | $184.78M | $163.79M | $178.18M | - | - | - | - | - | - | - | - |
| Product And Services, Royalties And Contract Revenue | - | - | - | - | $4.60M | $4.89M | $4.58M | $3.88M | $3.85M | $3.87M | $3.47M | $4.05M | $4.21M | $3.94M | $4.23M | $4.52M | $5.21M | $5.38M | $10.71M | $4.86M |
| Erwinaze And Erwinase | - | - | - | - | - | - | - | - | - | - | $28.31M | $41.07M | $56.58M | $20.14M | $32.68M | $37.73M | $54.92M | $34.02M | $27.62M | $60.90M |
| Product And Services, Product Sales | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $558.20M | $530.21M | $576.53M | $532.32M | $523.42M | $503.33M |
Jazz Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product And Services, Product Sales Net Of Deductions (45.96%), Xywav (17.56%), Total Oncology (13.22%), Epidiolex/Epidyolex (11.78%), Zepzelca (3.86%), Xyrem (2.96%), Defitelio/Defibrotide (2.17%), Vyxeos (2.05%), Sativex (0.30%), and Other Products (0.13%).
Jazz Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Europe | $239.64M | $230.16M | $175.21M | $150.20M | $125.91M |
| UNITED STATES | $3.37B | $2.82B | $2.14B | $1.97B | $1.73B |
| Other Countries | $49.36M | $43.84M | $43.82M | $46.24M | $37.44M |
Jazz Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (92.10%), Europe (6.55%), and Other Countries (1.35%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $924.59M | $808.21M | $884.71M | $810.12M | $903.62M | $867.84M | $858.34M | $740.58M | $823.82M | $757.23M | $690.90M | $548.29M | $601.55M | $548.41M | $516.10M | $478.48M | $529.16M | $492.37M | $480.93M | $462.86M |
| Europe | $82.16M | $71.36M | $59.33M | $65.90M | $57.81M | $60.02M | $60.78M | $61.03M | $65.62M | $70.73M | $47.27M | $47.23M | $49.98M | $45.78M | $37.90M | $41.56M | $43.24M | $35.04M | $36.52M | $35.40M |
| Other Countries | $17.07M | $22.41M | $13.28M | $16.80M | $10.70M | $12.79M | $13.76M | $12.11M | $7.29M | $10.16M | $13.64M | $12.06M | $13.99M | $6.70M | $8.44M | $14.69M | $9.34M | $10.30M | $16.68M | $9.92M |
Jazz Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (90.31%), Europe (8.02%), and Other Countries (1.67%).
Jazz Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals | $3.83B | $1.02B |
| INCY | Incyte | $3.70B | $1.04B |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| UTHR | United Therapeutics | $2.33B | $714.90M |
| EXEL | Exelixis | $1.83B | $637.18M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| ARGX | argenx SE | $1.23B | $401.00M |
| TECH | Bio-Techne | $1.16B | $303.43M |
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| DNLI | Denali Therapeutics | $330.53M | - |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| LQDA | Liquidia | $17.49M | $2.97M |
| INBX | Inhibrx | $1.80M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| PCVX | Vaxcyte | - | - |
| DICE | DICE Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
JAZZ Revenue FAQ
What is Jazz Pharmaceuticals’s yearly revenue?
Jazz Pharmaceuticals's yearly revenue for 2023 was $3.83B, representing an increase of 4.78% compared to 2022. The company's yearly revenue for 2022 was $3.66B, representing an increase of 18.26% compared to 2021. JAZZ's yearly revenue for 2021 was $3.09B, representing an increase of 30.91% compared to 2020.
What is Jazz Pharmaceuticals’s quarterly revenue?
Jazz Pharmaceuticals's quarterly revenue for Q2 2024 was $1.02B, a 13.51% increase from the previous quarter (Q1 2024), and a 6.95% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $901.98M, a -10.87% decrease from the previous quarter (Q4 2023), and a 1.03% increase year-over-year (Q1 2023). JAZZ's quarterly revenue for Q4 2023 was $1.01B, a 4.09% increase from the previous quarter (Q3 2023), and a 4.10% increase year-over-year (Q4 2022).
What is Jazz Pharmaceuticals’s revenue growth rate?
Jazz Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 23.91%, and for the last 5 years (2019-2023) was 77.36%.
What are Jazz Pharmaceuticals’s revenue streams?
Jazz Pharmaceuticals's revenue streams in c 22 are Epidiolex/Epidyolex, Defitelio/Defibrotide, Zepzelca, Xywav, Xyrem, Vyxeos, Total Oxybate, Sunosi, Sativex, Rylaze, Product And Services, Royalties And Contract Revenue, Product And Services, Product Sales Net Of Deductions, Other Products, Neuroscience, and Oncology. Epidiolex/Epidyolex generated $736.4M in revenue, accounting 5.70% of the company's total revenue, up 58.83% year-over-year. Defitelio/Defibrotide generated $194.29M in revenue, accounting 1.50% of the company's total revenue, down -1.84% year-over-year. Zepzelca generated $269.91M in revenue, accounting 2.09% of the company's total revenue, up 9.36% year-over-year. Xywav generated $958.42M in revenue, accounting 7.42% of the company's total revenue, up 79.05% year-over-year. Xyrem generated $1.02B in revenue, accounting 7.90% of the company's total revenue, down -19.38% year-over-year. Vyxeos generated $127.98M in revenue, accounting 0.99% of the company's total revenue, down -4.54% year-over-year. Total Oxybate generated $1.98B in revenue, accounting 15.32% of the company's total revenue, up 9.87% year-over-year. Sunosi generated $28.84M in revenue, accounting 0.22% of the company's total revenue, down -50.20% year-over-year. Sativex generated $16.82M in revenue, accounting 0.13% of the company's total revenue, up 32.41% year-over-year. Rylaze generated $281.66M in revenue, accounting 2.18% of the company's total revenue, up 228.93% year-over-year. Product And Services, Royalties And Contract Revenue generated $17.94M in revenue, accounting 0.14% of the company's total revenue, up 17.77% year-over-year. Product And Services, Product Sales Net Of Deductions generated $3.64B in revenue, accounting 28.20% of the company's total revenue, up 18.27% year-over-year. Other Products generated $6.64M in revenue, accounting 0.05% of the company's total revenue, down -32.20% year-over-year. Neuroscience generated $2.76B in revenue, accounting 21.38% of the company's total revenue, up 18.22% year-over-year. Oncology generated $873.84M in revenue, accounting 6.77% of the company's total revenue, up 19.08% year-over-year.
What is Jazz Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Jazz Pharmaceuticals was Product And Services, Product Sales Net Of Deductions. This segment made a revenue of $3.64B, representing 28.20% of the company's total revenue.